Director James Healy filed a Form 4 with the SEC on October 30, 2026, disclosing the purchase of a combined 969,480 shares of Rapport Therapeutics, Inc. common stock across four affiliated entities on October 28, 2026, all at a price of $21 per share.

Key Highlights

  • Reporting person: James Healy, listed as a Director of Rapport Therapeutics, Inc. (NASDAQ:RAPP), affiliated with Sofinnova Investments, Inc.
  • Transaction date: October 28, 2026, with all four purchases executed at $21 per share.
  • Largest purchase: 952,380 shares acquired indirectly through Sofinnova Venture Partners XI, L.P., bringing that entity's total beneficial ownership to 2,815,707 shares.
  • Additional purchases: 6,395 shares through SummitTX Master, SPC - SummitTX Apex SP - Healthcare 3; 3,772 shares through SummitTX Master, SPC - SummitTX Alpha SP - Healthcare 3; and 6,933 shares through SummitTX Pinnacle Master, L.P. - Healthcare 3.
  • Post-transaction holdings: Following reported transactions, indirect beneficial ownership stands at 17,990, 14,924, and 25,267 shares, respectively, for the three SummitTX entities.
  • Beneficial ownership disclaimer: Healy disclaims beneficial ownership of all shares reported for Section 16 purposes, except to the extent of his pecuniary interest, according to the filing.

Healy's October 28 Purchases Across Four Sofinnova-Affiliated Entities

According to the filing, all four purchases were coded "P" (open-market purchase) and carried a transaction price of $21 per share. The largest block, 952,380 shares, was acquired indirectly through Sofinnova Venture Partners XI, L.P. ("SVP XI"). The filing explains that Sofinnova Management XI, L.P. is the general partner of SVP XI, and Sofinnova Management XI, L.L.C. is in turn its general partner. Healy is described as a managing member of that entity and "may be deemed to share voting and dispositive power" over the shares held by SVP XI.

The remaining three purchases were made through entities for which Sofinnova BioEquities GP LLC ("BioEquities GP") serves as general partner. These were SummitTX Master, SPC - SummitTX Apex SP - Healthcare 3 (6,395 shares, post-transaction total 17,990); SummitTX Master, SPC - SummitTX Alpha SP - Healthcare 3 (3,772 shares, post-transaction total 14,924); and SummitTX Pinnacle Master, L.P. - Healthcare 3 (6,933 shares, post-transaction total 25,267). The filing notes that Healy is a managing member of BioEquities GP and "may be deemed to share voting and dispositive power" over shares held by each of those entities.

In each case, the filing states that Healy "disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any," and that the report "shall not be deemed an admission that he is a beneficial owner of such securities." No derivative securities transactions were reported. The filing was signed by Nathalie Auber as attorney-in-fact on October 30, 2026.

What Was Disclosed

Director James Healy disclosed four indirect purchases of Rapport Therapeutics common stock on October 28, 2026, totaling 969,480 shares across affiliated entities, all at $21 per share. Beneficial ownership disclaimers were included for all four positions.